Atara Biotherapeutics Stock Price. Everything You Need To Know About The Atara Biotherapeutics Stock!
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 334 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through the incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Its pipeline products include Tab-cel, ATA188, ATA2271, ATA3271, and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is used for the treatment of multiple sclerosis.
Atara Biotherapeutics Stock Price. Everything You Need To Know About The Atara Biotherapeutics Stock! performance
- Employees 334
- Company HQ Thousand Oaks
- Website https://www.atarabio.com/
- ATRA Asset Type Common Stock
- ATRA Market Capitalization 82.4M
- Earnings Per Share -2.61
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Atara Biotherapeutics is a rapidly growing biotechnology company that is making waves in the healthcare industry. With a mission to transform the lives of patients with serious medical conditions, Atara Biotherapeutics focuses on developing and commercializing innovative therapies. For retail investors from Malaysia, Thailand, Indonesia, and Vietnam who are looking to invest in the company, there are several avenues to explore. One of the most common ways is to invest through a brokerage account that offers access to US stocks. By opening an account with a reputable broker, investors can easily buy and sell Atara Biotherapeutics stock. Additionally, it is crucial for investors to conduct thorough research and stay updated with the latest news regarding the company’s performance, clinical trials, and potential partnerships. By staying informed and making informed decisions, retail investors from these countries can seize opportunities in this exciting biotech stock.
